Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

• Antoni Ribas,
• Paul Chapman,
• Katherine S Panageas,
• Michael Postow,
• Joyson Karakunnel,
• Hussein Tawbi,
• Christine Spencer,
• Katy Tsai,
• Ramy Ibrahim,
• Jedd Wolchok,
• Theresa LaVallee,
• Travis J Hollmann,
• Alexander Shoushtari,
• Daniel K Wells,
• Margaret Callahan,
• Samantha Bucktrout,
• Claire F Friedman,
• Christopher R Cabanski,
• Pier Gherardini,
• Richard O Chen

Affiliations

Antoni Ribas

Department of Medicine, University of California Los Angeles, Los Angeles, California, USA

Paul Chapman

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Katherine S Panageas

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Michael Postow

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Joyson Karakunnel

Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

Hussein Tawbi

Department of Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Christine Spencer

Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

Katy Tsai

Department of Medicine, University of California San Francisco, San Francisco, California, USA

Ramy Ibrahim

Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

Jedd Wolchok

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Theresa LaVallee

Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

Travis J Hollmann

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Alexander Shoushtari

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Daniel K Wells

Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

Margaret Callahan

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Samantha Bucktrout

Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

Claire F Friedman

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Christopher R Cabanski

Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

Pier Gherardini

Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

Richard O Chen

Personalis Inc, Menlo Park, California, USA